目的观察孟鲁斯特钠联合脾氨肽对哮喘患儿Th1/Th2细胞因子的影响及临床疗效。方法 106例支气管哮喘患儿随机分为对照组和观察组,各53例。对照组给予沙美特罗替卡松粉吸入剂吸入,观察组加服孟鲁司特钠和脾氨肽冻干粉,疗程均为3个月。治疗前后分别测定患儿外周血白细胞介素-4(IL-4)、干扰素-γ(INF-γ)、肺功能及哮喘控制测试评分(ACT)。结果两组治疗后IL-4均较治疗前明显降低,而INF-γ较治疗前明显升高,且观察组较对照组变化更为明显,差异有统计学意义(P<0.05)。两组治疗后肺功能均较治疗前明显好转,ACT评分均较治疗前明显增高,且观察组较对照组治疗后也有显著的肺功能改善和ACT评分增高,差异有统计学意义(P<0.05)。结论孟鲁司特钠联合脾氨肽能更有效地改善哮喘患儿的肺功能、调节细胞免疫及控制哮喘发作。 Objective To observe the effect of montelukast combined with splenic ammonia on Th1 / Th2 cytokines in asthmatic children and its clinical efficacy. Methods 106 cases of children with bronchial asthma were randomly divided into control group and observation group, 53 cases each. The control group was given inhaled salmeterramide powder inhalation, the observation group plus montelukast sodium and spleen ammonia peptide lyophilized powder, treatment for 3 months. Peripheral blood levels of IL-4, INF-γ, pulmonary function and asthma control test (ACT) were measured before and after treatment. Results After treatment, IL-4 in both groups was significantly lower than that before treatment, while INF-γ was significantly higher than that before treatment, and the changes in the observation group were more obvious than those in the control group. The difference was statistically significant (P <0.05). The lung function of the two groups after treatment was significantly better than before treatment, ACT scores were significantly higher than before treatment, and the observation group than the control group after treatment also significantly improved pulmonary function and ACT score increased, the difference was statistically significant (P <0.05 ). Conclusion Montelukast combined with spleen ammonia peptide can effectively improve the lung function, regulate cellular immunity and control the asthma attack in children with asthma.